Medscape www.medscape.com

References for:
White Paper on Herbal Products

[Pharmacotherapy 20(7):877-891, 2000. © 2000 Pharmacotherapy Publications]

  1. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States: prevalence, costs and patterns of use. N Engl J Med 1993;328:246-52.
  2. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. Results of a follow-up national survey. JAMA 1998; 280:1569-75.
  3. Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998;279:1548-53.
  4. Johnston BA. One-third of nation's adults use herbal remedies: market estimated at $3.24 billion. HerbalGram 1997;40:49.
  5. Coleman LM, Fowler LL, Williams ME. Use of unproven therapies by people with Alzheimer's disease. J Am Geriatr Soc 1995;43:747-50.
  6. Dalen JE. "Conventional" and "unconventional" medicine. Can they be integrated? Arch Intern Med 1998;158:2179-81.
  7. Anonymous. Herbal roulette. Consumer Reports. November 1995:698-705.
  8. Winslow LC, Kroll DJ. Herbs as medicines. Arch Intern Med 1998;158:2192-9.
  9. Miller LG. Herbal medicinals. Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158:2200-11.
  10. Gugliotta G. Health concerns grow over herbal ads. Washington Post. March 19, 2000:A01.
  11. Abbot NC, White AR, Ernst E. Complementary medicine. Nature 1996;381:361.
  12. Perharic L, Shaw D, Murray V. Toxic effects of herbal medicine and food supplements. Lancet 1993;324:180-1.
  13. Sandler B, Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urology 1993;41:343-5.
  14. Holbein MEB, Knochel JP. Renal implications of herbal remedies. In: Miller LG, Murray WJ, eds. Herbal medicinals: a clinician's guide. Binghamton, NY: Haworth Press, 1998:9-35.
  15. Weisbord SD, Soule JB, Kimmel PL. Poison on line: acute renal failure caused by oil of wormwood purchased through the Internet. N Engl J Med 1997;337:825-7.
  16. Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf. J Clin Gastroenterol 1990;12:20(7)-6.
  17. Gordon DW, Rosenthal G, Hart J, Sirota R, Baker AL. Chaparral ingestion: the broadening spectrum of liver injury caused by herbal medications. JAMA 1995;273:489-90.
  18. Winship KA. Toxicity of comfrey. Adverse Drug React Toxicol Rev 1991;10:47-59.
  19. Segelman AB, Segelman FP, Karliner J, Sofia D. Sassafras and herb tea: potential health hazards. JAMA 1976;236:477.
  20. Siegers CP, Von Hertzberg-Lottin E, Otte M. Anthranoid laxative abuse: a risk of colorectal cancer? Gut 1993;34:1099-101.
  21. Surh YJ, Lee SS. Capsaicin in hot chili pepper: carcinogen, co-carcinogen or anticarcinogen. Fed Chem Toxicol 1996;34:313-16.
  22. Janetzky K, Morreale AP. Probableinteractions between warfarin and ginseng. Am J Health-Syst Pharm 1997;54:692-3.
  23. Cooperative Group for Essential Oil of Garlic. The effect of essential oil of garlic on hyperlipidemia and platelet aggregation: an analysis of 308 cases. J Trad Chinese Med 1986;6:117-20.
  24. Backon J. Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry. Med Hypothesis 1986;20:271-8.
  25. Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behavior via neutralization of sulfhydryl groups. J Pharm Pharmacol 1987;39:459-65.
  26. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic ginkgo biloba ingestion. Neurology 1996;46:1775-6.
  27. Dandekar U, Chandra RS, Dalvi SS, et al. Analysis of a clinically important interaction between phenytoin and Shankhapushpi, an Ayurvedic preparation. J Ethnopharmacol 1992;35:285-8.
  28. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John's wort [letter]. Lancet 2000;355:547-8.
  29. Anonymous. Herbal products. Prescriber's letter. 1998;5:64-5.
  30. Patterson E. Standardized extracts: herbal medicine of the future? Herb Market Rev 1996;2:37-8.
  31. Liberti LE, DerMarderosian AD. Evaluation of commercial ginseng products. J Pharmaceut Sci 1978;67:1487-9.
  32. Heptinstall S, Awang DVS, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (l.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol 1992;44:391-5.
  33. U.S. Food and Drug Administration. Current good manufacturing practice in manufacturing, packing or holding dietary supplements; proposed rule. Federal Register. February 6, 1997;62:5700-9.
  34. Blumenthal M. Industry alert: plantain adulterated with digitalis. HerbalGram 1997;40:28-9.
  35. Murch SJ, Simmons CB, Saxene PK. Melatonin in feverfew and other medicinal plants. Lancet 1997;350:1598-9.
  36. Norcross WA, Ganiats TG, Ralph LP, Seidel RG, Ikeda TS. Accidental poisoning by warfarin-contaminated herbal tea. Western J Med 1993;159:80-2.
  37. U.S. Food and Drug Administration. FDA warns consumers against taking dietary supplement "Sleeping Buddha." March 12, 1998. Available from: http://www.fda.gov/bbs/topics/news/ new00625.html.
  38. Lightfoote J, Blair J, Cohen JR. Lead intoxication in an adult caused by Chinese herbal medication. JAMA 1977;238:1539.
  39. Awang DVC. Feverfew products. Can Med Assoc J. 1997;157:510-11.
  40. Blumenthal M. Testing botanicals: a report on developing the scientific and clinical evidence to support the clinical use of heterogeneous botanical products. HerbalGram 1997;40:43-6.
  41. Newall C, Anderson LA, Phillipson JD. St. John's wort monograph. In: Newall, C, Anderson LA, Phillipson JD, eds. Herbal Medicines. London: The Pharmaceutical Press, 1990:250-2.
  42. Anonymous. The PharmaPrint Process. Available from: http://www.pharmaprint.com.
  43. Briggs K. Univera develops only available method to authenticate botanics in dietary supplement market. Press release for Univera Pharmaceuticals, Inc., 100 Technology Drive, Suite 160, Broomfield, CO 80021. January 12, 2000.
  44. Bower H. Double standards exist in judging traditional and alternative medicine. BMJ 1998;316:1694.
  45. U.S. Food and Drug Administration. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Federal Register January 6, 2000;65:1000-50.
  46. U.S. Food and Drug Administration. FDA finalized rules for claims on dietary supplements. FDA talk paper. January 5, 2000. Available from: http://www.fda.gov/bbs/topics/answers/ an500994_html .
  47. Childs ND. FDA bans Cholestin, rules it contains lovastatin. Int Med News. June 15, 1998:8.
  48. Tyler VE. What pharmacists should know about herbal remedies. J Am Pharm Assoc 1996;NS36:29-37.
  49. Johnson I. Fight over rice yeast pits Chinese medicine against Western ways. Wall Street Journal. December 3, 1997. Available from: http://www.plant.uoguelph.ca/riskcomm/ archives/fsnet/ 1997/12-1997/fs-12/03-97-01.txt.
  50. U.S. Food and Drug Administration. Dietary supplement strategy (ten year plan). Center for Food Safety and Applied Nutrition. Washington, DC. January 2000. Available from: http://vm.cfsan.fda.gov/~dms/ds-strat.html.
  51. Evidence-Based Medicine Working Group. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 1992; 268:240-8.
  52. Guyatt GH, Cook DJ, Sackett DL, Eckman M, Pauker S. Grades of recommendation for antithrombotic agents. Chest 1998;114(suppl):441S-4.
  53. Tyler VE. Herbs and phytomedicinal products. In: Handbook of nonprescription drugs, 11th ed. Washington, DC: American Pharmaceutical Association, 1996:695.
  54. Leaders FE Jr. Incorporating botanical products into MCO formularies. Drug Benefit Trends 1998;10:34-43.
  55. Eisenberg DM. Advising patients who seek alternative medical therapies. Ann Intern Med 1997;127:61-9.
  56. Meinhardt RA, Richardson C, Ohlinger P. Alternative medicine and pharmacists' counseling obligations. Drug Benefit Trends 1998;10:24, 28.
  57. Miller LG, Murray WJ. Herbal instruction in United States pharmacy schools. Am J Pharm Educ 1997;61:160-2.
  58. Rowell DM, Kroll DJ. Complementary and alternative medicine education in United States pharmacy schools. Am J Pharm Educ 1998;62:412-19.
  59. Anonymous. Revised accreditation standards of the American Council on Pharmaceutical Education. Chicago: ACPE, June 1997.
  60. Anonymous. Ovid Scope Notes. Bethesda, MD: National Library of Medicine, 1997.
  61. National Institutes of Health. CM Field Registry Coordinator's biannual report to NIH (National Institutes of Health): Bethesda, MD: NIH, September 1997.
  62. National Institutes of Health. What is complementary and alternative medicine? Available from: http://nccam.nih.gov/ nccam/fcp/faq/index.html#what-is.
  63. The Cochrane Library. The complementary medicine field module. The Cochrane Library [database on disk and CD-ROM]. The Cochrane Collaboration, issue 2 (updated quarterly). Oxford: Cochrane Library. Updated software, 1998.
  64. The Qigong Association of America. Answers to frequently asked questions. What is Qigong? Available from: http://www.qi.org/faq.htm.
  65. Jahnke R. Health-care: China's ancient solution to the crisis in modern medicine. QI: the Journal of Traditional Eastern Health & Fitness, 1995. Available from: http://www.qi-journal.com/ jahnke.html#anchor 585346.
  66. Hulke M, ed. The encyclopedia of alternative medicine and self-help. New York: Schocken books, 1979.